What is your preferred way of administering nivolumab/ipilimumab in GI cancers?

Thanks for the question.

My preference would be Nivo 3 Q2W & ipi 1 Q6W due to the more favorable toxicity profile seen in the first-line CheckMate-142 trial (Lenz et al., PMID 34637336) compared to CheckMate-142 that was conducted in refractory setting (Overman et al., PMID 29355075).

Thanks